Up-regulation of NKG2D ligands by AML cells to increase sensitivity to NK cells: the tumour might strike back. Comment on "differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis" by Rohner et al. [Leuk Res 2007;31:1393-402].
Zimmer
Jacques
J
Michel
Tatiana
T
Andrès
Emmanuel
E
Hentges
François
F
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism*; D008024:Ligands; D055655:NK Cell Lectin-Like Receptor Subfamily K; D011971:Receptors, Immunologic / Q000819:agonists / Q000378:metabolism*; D055607:Receptors, Natural Killer Cell; D015854:Up-Regulation
D000970:Antineoplastic Agents; C527085:KLRK1 protein, human; D008024:Ligands; D055655:NK Cell Lectin-Like Receptor Subfamily K; D011971:Receptors, Immunologic; D055607:Receptors, Natural Killer Cell